Before deciding the "societal value" of the new medicine, its performance in clinical trials, possible side effects, and accessibility must be closely examined.
Lecanemab is the first drug proven to slow the progression of Alzheimer's. Its manufacturer Eisai calculated its societal value to determine a suitable price.
A Japanese research team has found a way to improve genome editing, but complex regulations hinder Japanese technology from reaching the clinical stage.
The improved accuracy in CRISPR-Cas9 genome editing could reduce the risk of cancerous cell transformation in gene therapy using this technology.
By fighting misinformation about the HPV vaccine to save lives, medical doctor Riko Muranaka has shown the cost and value of defending scientific integrity.
Japan is one of the world's leading producers of industrial robots, but its surgical robot development lagged until the introduction of Medicaroid's hinotori.
“We were able to reach the starting line of a new medical therapy,” said Dr Ryuichi Okamoto about the new regenerative treatment for ulcerative colitis.
iPS cells are moving from clinical trialsーeye disease, Parkinson’s disease, heart failure, cancer, spinal cord injuriesーto the stage of practical application.
Few manufacturers — such as Japan’s Eisai and the U.S.’ Biogen — have continued to develop a treatment. We hope the health ministry announces the approval...
Graduate student’s study of how sea slugs regenerate their lost, damaged or cut-off parts can be unraveled could bring new hope to regenerative medicine for humans.
iPS cell research is moving ahead quickly with promising applications for COVID-19, diseases affecting vision and muscular function, among others. The issue to overcome next is...
Getting started with the world of ukiyo-e can feel a bit daunting. After all, how does one even begin to understand the art of...
